Scarica l'app Stockscreener
179.25
0.07%
-0.3272
Charles River Laboratories International Inc Borsa (CRL) Ultime notizie
Charles River Laboratories International (CRL) Faces Biotech R&D Spending Headwinds - Yahoo Finance
Picton Mahoney Asset Management Boosts Stock Holdings in Charles River Laboratories International, Inc. $CRL - MarketBeat
LaPlume buys Charles River Labs [CRL] shares worth $4363 - Investing.com
How Charles River Laboratories International Inc. (CRL) Affects Rotational Strategy Timing - Stock Traders Daily
Charles River Laboratories: Why Wall Street Suddenly Cares About This Quiet Biotech Powerhouse - AD HOC NEWS
Insider Buying: Joseph Laplume Acquires Shares in Charles River Laboratories International Inc (CRL) - GuruFocus
Charles River (NYSE: CRL) CEO receives 16,796-share stock-based award - Stock Titan
Charles River (NYSE: CRL) EVP adds 25 shares in open-market buy - Stock Titan
Charles River Laboratories: Is Wall Street Underpricing This Quiet Biotech Enabler? - AD HOC NEWS
Charles River (CRL) Trims 2026 Outlook After Divestitures and Leadership Changes Is The Strategy Working? - simplywall.st
Charles River Laboratories International, Inc. $CRL Shares Sold by Citigroup Inc. - MarketBeat
Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Assessing Charles River Laboratories (CRL) Valuation After Recent Mixed Share Price Performance - simplywall.st
Charles River expands footprint at Heriot-Watt University Research Park - Heriot-Watt University
Charles River Laboratories to Present at TD Cowen and Barclays Conferences - Business Wire
Charles River Laboratories (CRL) Stock Analysis: Navigating the Healthcare Research Sector with 10.48% Upside Potential - DirectorsTalk Interviews
Charles River Laboratories Experiences Evaluation Revision Amidst Mixed Market Indicators - Markets Mojo
Could Cash Machine Charles River Laboratories International Stock Be Your Next Buy? - Trefis
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
Charles River Laboratories parts ways with its CDMO business - European Pharmaceutical Review
Charles River Laboratories International, Inc. $CRL Stock Holdings Increased by JPMorgan Chase & Co. - MarketBeat
Charles River Laboratories to divest a number of assets to IQVIA and GI Partners - Business Weekly
IQVIA to acquire Charles River drug discovery assets - Yahoo Finance
Charles River to sell CDMO and European discovery assets By Investing.com - Investing.com Australia
Charles River Laboratories Experiences Revision in Its Stock Evaluation Amid Mixed Financial Indicators - Markets Mojo
UBS Group Issues Positive Forecast for Charles River Laboratories International (NYSE:CRL) Stock Price - MarketBeat
Activist investor prompts sale of Charles River CDMO business, U.S. and European sites - The Business Journals
IQVIA Holdings Inc. (NYSE : IQV) entered into a definitive agreement to acquire European Discovery Services Assets from Charles River Laboratories International, Inc. (NYSE - marketscreener.com
Charles River Laboratories (CRL) Announces Strategic Divestitures to Streamline Operations - GuruFocus
UBS Adjusts Price Target on Charles River Laboratories International to $175 From $170, Maintains Neutral Rating - marketscreener.com
Sector Update: Health Care - marketscreener.com
Charles River Labs Breaks The Mold, Announces Bold Divestiture Plans - Benzinga
Charles River announces divestitures, updates guidance - MSN
Charles River to sell CDMO and European discovery assets - Investing.com
Charles River Laboratories stock rises on divestiture plans By Investing.com - Investing.com Australia
IQVIA to acquire drug discovery assets from Charles River Labs - Investing.com
Charles River Laboratories to divest CDMO, Cell Solutions, and European assets - Investing.com Australia
Charles River Laboratories to Sell Certain European Assets, Businesses; Full-Year 2026 Guidance Updated - marketscreener.com
Iqvia to Acquire Discovery Services from Charles River Laborator - GuruFocus
Charles River Laboratories (CRL) to Divest European Assets for $145M - GuruFocus
Charles River raises annual profit view as it sells underperforming assets - marketscreener.com
Charles River Labs divests units to sharpen profitability focus - TipRanks
Charles River Laboratories to divest CDMO, Cell Solutions, and European assets By Investing.com - Investing.com South Africa
Charles River Laboratories to divest CDMO, Cell Solutions and European discovery assets; updates 2026 guidance - TradingView
Charles River Laboratories International, Inc. recently disclosed that its asset divestiture plan is expected to have a significant impact on overall revenue for fiscal year 2026, with a projected reduction of more than 200 millions USD. - Bitget
Charles River (NYSE: CRL) plans two divestitures and trims 2026 revenue - Stock Titan
(CRL) Charles River Laboratories Expects 2026 Adjusted EPS Including Impact of Planned Divestitures Range $10.80$11.30 - marketscreener.com
Iqvia signs agreement to acquire drug discovery assets from Charles River Laboratories, expanding end-to-end drug discovery capabilities - marketscreener.com
IQVIA to acquire drug discovery assets from Charles River Labs By Investing.com - Investing.com South Africa
Charles River Laboratories Provides Update on Planned Divestitures - ChartMill
Baird Maintains Outperform Rating on Charles River Laboratories International, Inc. (CRL) - Insider Monkey
Baird maintains outperform rating on Charles River Laboratories International, Inc. (CRL) - MSN
IQVIA Holdings Inc. (IQV) Offers Impressive Upside Despite AI-Linked Threats - Bitget
Charles River Stock Has Dropped 28% Over the Past Month: Here’s What to Expect in 2026 - TIKR.com
Why Charles River Laboratories (CRL) is a Top Value Stock for the Long-Term - Yahoo Finance
Hillsdale Investment Management Inc. Grows Stock Position in Charles River Laboratories International, Inc. $CRL - MarketBeat
Assessing Charles River Laboratories (CRL) Valuation After Earnings Beat And 2026 Improvement Guidance - simplywall.st
Charles River Laboratories (CRL) Stock Analysis: A 16.86% Upside Amidst Strategic Collaborations - DirectorsTalk Interviews
1.93%
0.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):